Associated Papers
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
Stiff A et al.
Nature Genetics, 2024
39367245 (PubMed )
Supplement: 41588_2024_1929_MOESM1_ESM.pdf
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
37304756 (PubMed )
Supplement: zcad025_supplemental_files.zip › Supplementary_Table_2.xlsx › PVs
Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy.
Zhang Y et al.
Cell Reports, 2021
34788622 (PubMed )
Supplement: NIHMS1757901-supplement-2.xlsx › SNVs_indels
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.
Pleasance E et al.
Nature Cancer, 2020
35121966 (PubMed )
Supplement: 43018_2020_50_MOESM3_ESM.xlsx › Supplementary_Table_5
Prediction of acute myeloid leukaemia risk in healthy individuals.
Abelson S et al.
Nature, 2018
29988082 (PubMed )
Supplement: NIHMS77608-supplement-Supplementary_Table_2.xlsx › 2.1_DC_ARCH-PD
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.
Köbel M et al.
The Journal of Pathology. Clinical Research, 2016
27840695 (PubMed )
Supplement: CJP2-2-247-s010.xlsx › Koebel_TP53_data.txt
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Nik-Zainal S et al.
Nature, 2016
27135926 (PubMed )
Supplement: NIHMS68344-supplement-Supplementary_Tables_1-21.zip › nature17676-s3 › Supplementary_Table_14.Driver.Events.By.Mutation.Type.01052015.v2.xlsx › Subs.indels
TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset.
Pinto C et al.
Familial Cancer, 2009
Molecular genetics and diversity of choroid plexus tumors.
Thomas C et al.
Neuro-oncology Advances, 0
Select a paper to view details